Literature DB >> 24658816

The erythroid function of transferrin receptor 2 revealed by Tmprss6 inactivation in different models of transferrin receptor 2 knockout mice.

Antonella Nai1, Rosa M Pellegrino2, Marco Rausa1, Alessia Pagani1, Martina Boero2, Laura Silvestri1, Giuseppe Saglio2, Antonella Roetto2, Clara Camaschella3.   

Abstract

Transferrin receptor 2 (TFR2) is a transmembrane glycoprotein expressed in the liver and in the erythroid compartment, mutated in a form of hereditary hemochromatosis. Hepatic TFR2, together with HFE, activates the transcription of the iron-regulator hepcidin, while erythroid TFR2 is a member of the erythropoietin receptor complex. The TMPRSS6 gene, encoding the liver-expressed serine protease matriptase-2, is the main inhibitor of hepcidin and inactivation of TMPRSS6 leads to iron deficiency with high hepcidin levels. Here we evaluate the phenotype resulting from the genetic loss of Tmprss6 in Tfr2 total (Tfr2(-/-)) and liver-specific (Tfr2(LCKO)) knockout mice. Tmprss6(-/-)Tfr2(-/-) and Tmprss6(-/-)Tfr2(LCKO) mice have increased hepcidin levels and show iron-deficiency anemia like Tmprss6(-/-)mice. However, while Tmprss6(-/-)Tfr2(LCKO) are phenotypically identical to Tmprss6(-/-) mice, Tmprss6(-/-)Tfr2(-/-) mice have increased red blood cell count and more severe microcytosis than Tmprss6(-/-) mice. In addition hepcidin expression in Tmprss6(-/-)Tfr2(-/-) mice is higher than in the wild-type animals, but lower than in Tmprss6(-/-) mice, suggesting partial inhibition of the hepcidin activating pathway. Our results prove that hepatic TFR2 acts upstream of TMPRSS6. In addition Tfr2 deletion causes a relative erythrocytosis in iron-deficient mice, which likely attenuates the effect of over-expression of hepcidin in Tmprss6(-/-) mice. Since liver-specific deletion of Tfr2 in Tmprss6(-/-) mice does not modify the erythrocyte count, we speculate that loss of Tfr2 in the erythroid compartment accounts for the hematologic phenotype of Tmprss6(-/-)Tfr2(-/-) mice. We propose that TFR2 is a limiting factor for erythropoiesis, particularly in conditions of iron restriction. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24658816      PMCID: PMC4040905          DOI: 10.3324/haematol.2013.103143

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  36 in total

1.  Comparison of 3 Tfr2-deficient murine models suggests distinct functions for Tfr2-alpha and Tfr2-beta isoforms in different tissues.

Authors:  Antonella Roetto; Ferdinando Di Cunto; Rosa Maria Pellegrino; Emilio Hirsch; Ornella Azzolino; Alessandro Bondi; Ilaria Defilippi; Sonia Carturan; Barbara Miniscalco; Fulvio Riondato; Daniela Cilloni; Lorenzo Silengo; Fiorella Altruda; Clara Camaschella; Giuseppe Saglio
Journal:  Blood       Date:  2010-02-23       Impact factor: 22.113

2.  Regulation of TMPRSS6 by BMP6 and iron in human cells and mice.

Authors:  Delphine Meynard; Valentina Vaja; Chia Chi Sun; Elena Corradini; Shanzhuo Chen; Carlos López-Otín; Lovorka Grgurevic; Charles C Hong; Marit Stirnberg; Michael Gütschow; Slobodan Vukicevic; Jodie L Babitt; Herbert Y Lin
Journal:  Blood       Date:  2011-05-26       Impact factor: 22.113

3.  Regulation of expression of murine transferrin receptor 2.

Authors:  H Kawabata; R S Germain; T Ikezoe; X Tong; E M Green; A F Gombart; H P Koeffler
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

4.  Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis.

Authors:  Hana Forejtnikovà; Maud Vieillevoye; Yael Zermati; Mireille Lambert; Rosa Maria Pellegrino; Soizic Guihard; Muriel Gaudry; Clara Camaschella; Catherine Lacombe; Antonella Roetto; Patrick Mayeux; Frédérique Verdier
Journal:  Blood       Date:  2010-09-08       Impact factor: 22.113

5.  How I treat unexplained refractory iron deficiency anemia.

Authors:  Chaim Hershko; Clara Camaschella
Journal:  Blood       Date:  2013-11-08       Impact factor: 22.113

6.  An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.

Authors:  Paul J Schmidt; Iva Toudjarska; Anoop K Sendamarai; Tim Racie; Stuart Milstein; Brian R Bettencourt; Julia Hettinger; David Bumcrot; Mark D Fleming
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

7.  Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice.

Authors:  Shuling Guo; Carla Casu; Sara Gardenghi; Sheri Booten; Mariam Aghajan; Raechel Peralta; Andy Watt; Sue Freier; Brett P Monia; Stefano Rivella
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

8.  A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium.

Authors:  Nicole Soranzo; Tim D Spector; Massimo Mangino; Brigitte Kühnel; Augusto Rendon; Alexander Teumer; Christina Willenborg; Benjamin Wright; Li Chen; Mingyao Li; Perttu Salo; Benjamin F Voight; Philippa Burns; Roman A Laskowski; Yali Xue; Stephan Menzel; David Altshuler; John R Bradley; Suzannah Bumpstead; Mary-Susan Burnett; Joseph Devaney; Angela Döring; Roberto Elosua; Stephen E Epstein; Wendy Erber; Mario Falchi; Stephen F Garner; Mohammed J R Ghori; Alison H Goodall; Rhian Gwilliam; Hakon H Hakonarson; Alistair S Hall; Naomi Hammond; Christian Hengstenberg; Thomas Illig; Inke R König; Christopher W Knouff; Ruth McPherson; Olle Melander; Vincent Mooser; Matthias Nauck; Markku S Nieminen; Christopher J O'Donnell; Leena Peltonen; Simon C Potter; Holger Prokisch; Daniel J Rader; Catherine M Rice; Robert Roberts; Veikko Salomaa; Jennifer Sambrook; Stefan Schreiber; Heribert Schunkert; Stephen M Schwartz; Jovana Serbanovic-Canic; Juha Sinisalo; David S Siscovick; Klaus Stark; Ida Surakka; Jonathan Stephens; John R Thompson; Uwe Völker; Henry Völzke; Nicholas A Watkins; George A Wells; H-Erich Wichmann; David A Van Heel; Chris Tyler-Smith; Swee Lay Thein; Sekar Kathiresan; Markus Perola; Muredach P Reilly; Alexandre F R Stewart; Jeanette Erdmann; Nilesh J Samani; Christa Meisinger; Andreas Greinacher; Panos Deloukas; Willem H Ouwehand; Christian Gieger
Journal:  Nat Genet       Date:  2009-10-11       Impact factor: 38.330

9.  Lack of the bone morphogenetic protein BMP6 induces massive iron overload.

Authors:  Delphine Meynard; Léon Kautz; Valérie Darnaud; François Canonne-Hergaux; Hélène Coppin; Marie-Paule Roth
Journal:  Nat Genet       Date:  2009-03-01       Impact factor: 38.330

10.  Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression.

Authors:  Junwei Gao; Juxing Chen; Maxwell Kramer; Hidekazu Tsukamoto; An-Sheng Zhang; Caroline A Enns
Journal:  Cell Metab       Date:  2009-03       Impact factor: 27.287

View more
  17 in total

1.  Is erythroferrone finally the long sought-after systemic erythroid regulator of iron?

Authors:  Alfons Lawen
Journal:  World J Biol Chem       Date:  2015-08-26

2.  Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity.

Authors:  Carla Casu; Mariateresa Pettinato; Alison Liu; Mariam Aghajan; Vania Lo Presti; Maria Rosa Lidonnici; Kevin A Munoz; Emir O'Hara; Violante Olivari; Simona Maria Di Modica; Sheri Booten; Shuling Guo; Garry Neil; Reem Miari; Nir Shapir; Inbal Zafir-Lavie; Hagit Domev; Giuliana Ferrari; Despina Sitara; Antonella Nai; Stefano Rivella
Journal:  Blood       Date:  2020-10-22       Impact factor: 22.113

3.  Tfr2 suppression benefits β-thalassemic erythropoiesis.

Authors:  Yelena Z Ginzburg; Robert E Fleming
Journal:  Blood       Date:  2018-11-22       Impact factor: 22.113

4.  Extrahepatic deficiency of transferrin receptor 2 is associated with increased erythropoiesis independent of iron overload.

Authors:  Aaron M Wortham; Devorah C Goldman; Juxing Chen; William H Fleming; An-Sheng Zhang; Caroline A Enns
Journal:  J Biol Chem       Date:  2020-02-13       Impact factor: 5.157

5.  Lobe specificity of iron binding to transferrin modulates murine erythropoiesis and iron homeostasis.

Authors:  Nermi L Parrow; Yihang Li; Maria Feola; Amaliris Guerra; Carla Casu; Princy Prasad; Luke Mammen; Faris Ali; Edvinas Vaicikauskas; Stefano Rivella; Yelena Z Ginzburg; Robert E Fleming
Journal:  Blood       Date:  2019-10-24       Impact factor: 22.113

Review 6.  The Regulation of Iron Absorption and Homeostasis.

Authors:  Daniel F Wallace
Journal:  Clin Biochem Rev       Date:  2016-05

Review 7.  What can we learn from ineffective erythropoiesis in thalassemia?

Authors:  Paraskevi Rea Oikonomidou; Stefano Rivella
Journal:  Blood Rev       Date:  2017-10-03       Impact factor: 8.250

8.  Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model.

Authors:  Irene Artuso; Maria Rosa Lidonnici; Sandro Altamura; Giacomo Mandelli; Mariateresa Pettinato; Martina U Muckenthaler; Laura Silvestri; Giuliana Ferrari; Clara Camaschella; Antonella Nai
Journal:  Blood       Date:  2018-09-12       Impact factor: 22.113

9.  Regulation of cell surface transferrin receptor-2 by iron-dependent cleavage and release of a soluble form.

Authors:  Alessia Pagani; Maud Vieillevoye; Antonella Nai; Marco Rausa; Meriem Ladli; Catherine Lacombe; Patrick Mayeux; Frédérique Verdier; Clara Camaschella; Laura Silvestri
Journal:  Haematologica       Date:  2015-01-30       Impact factor: 9.941

10.  The second transferrin receptor regulates red blood cell production in mice.

Authors:  Antonella Nai; Maria Rosa Lidonnici; Marco Rausa; Giacomo Mandelli; Alessia Pagani; Laura Silvestri; Giuliana Ferrari; Clara Camaschella
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.